1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (2984)
  2. Meeting Abstract (2527)
  3. Review (137)
  4. Editorial (106)
  5. Book Section (54)
  6. Research Letter (41)
  7. Guidelines (18)
  8. Correspondence (16)
  9. Miscellaneous (15)
  10. Conference Paper (13)
  11. Book Whole (3)
Groups
  1. Human Oncology and Pathogenesis Program (5914)
  2. GSK Faculty (5697)
  3. Department of Medicine (4259)
  4. Department of Pathology and Laboratory Medicine (3037)
  5. Tow Center for Developmental Oncology (TCDO) (2613)
  6. Solid Tumor Oncology Division (2600)

More Groups

People
  1. Marc Ladanyi (1327)
  2. David Solit (779)
  3. Ross Levine (774)
  4. Michael Berger (765)
  5. Nikolaus Schultz (486)
  6. Maria Arcila (426)

More People

Years
  1. 2025 (120)
  2. 2024 (359)
  3. 2023 (402)
  4. 2022 (451)
  5. 2021 (380)
  6. 2020 (457)

More Years

Publications
  1. Journal of Clinical Oncology (636)
  2. Blood (495)
  3. Cancer Research (412)
  4. Modern Pathology (299)
  5. Clinical Cancer Research (268)
  6. Laboratory Investigation (263)

More Publications

Publishers
  1. American Association for Cancer Research (871)
  2. Nature Publishing Group (758)
  3. American Society of Clinical Oncology (702)
  4. American Society of Hematology (541)
  5. Elsevier Inc. (420)
  6. Nature Research (312)

More Publishers

Results (5914)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A pharmacologic inhibitor of the protease taspase1 effectively inhibits breast and brain tumor growth
    Journal Article

    Chen, D. Y.; Lee, Y.; Van Tine, B. A.; Searleman, A. C.; Westergard, T. D.; Liu, H.; Tu, H. C.; Takeda, S.; Dong, Y.; Piwnica-Worms, D. R.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data
    Journal Article

    Wang, L.; Motoi, T.; Khanin, R.; Olshen, A.; Mertens, F.; Bridge, J.; Cin, P. D.; Antonescu, C. R.; Singer, S.; Hameed, M.; more...
    Genes Chromosomes and Cancer (2012)

    Fulltext@MSK | Save
  • Genetics of the myeloproliferative neoplasms
    Book Section

    Abdel-Wahab, O.; Levine, R. L.
    In Verstovsek, S.; Tefferi, A. (Eds.) Myeloproliferative Neoplasms: Biology and Therapy (2011)

    Fulltext@MSK | Save
  • Targeted therapy with small molecule kinase inhibitors
    Book Section

    Sawyers, C. L.
    In DeVita, V. T. Jr; Lawrence, T. S.; Rosenberg, S. A. (Eds.) Cancer: Principles & Practice of Oncology: Primer of the Molecular Biology of Cancer. 1st ed (2011)

    Fulltext@MSK | Save
  • Prostate cancer
    Book Section

    Chen, Y.; Arora, V. K.; Sawyers, C. L.
    In DeVita, V. T. Jr; Lawrence, T. S.; Rosenberg, S. A. (Eds.) Cancer: Principles & Practice of Oncology: Primer of the Molecular Biology of Cancer. 1st ed (2011)

    Fulltext@MSK | Save
  • A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive advanced castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Slovin, S. F.; Morris, M. J.; Steinbrecher, J. E.; Chen, Y.; Fleisher, M.; Larson, S. M.; Sawyers, C. L.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Clinical, pathologic, and molecular characteristics of patients with non-small cell lung cancer harboring mutations in PIK3CA
    Meeting Abstract

    Pietanza, M. C.; Arcila, M. E.; Chaft, J. E.; Zakowski, M. F.; Ladanyi, M.; Riely, G. J.; Kris, M. G.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Maintained sensitivity to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant lung cancers that recur after adjuvant TKI
    Meeting Abstract

    Oxnard, G. R.; Janjigian, Y. Y.; Arcila, M. E.; Kris, M. G.; Ladanyi, M.; Azzoli, C. G.; Miller, V. A.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Response to EGFR TKIs in never smokers with stage IV EGFR mutant squamous cell carcinoma of the lung (SQCC)
    Meeting Abstract

    Paik, P. K.; Rekhtman, N.; Riely, G. J.; Miller, V. A.; Ladanyi, M.; Kris, M. G.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM)
    Meeting Abstract

    Omuro, A. M. P.; Beal, K.; Karimi, S.; Correa, D.; Chan, T. A.; DeAngelis, L. M.; Gavrilovic, I. T.; Nolan, C.; Hormigo, A.; Lassman, A. B.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save